Novo Holdings announces 2025 Annual Results Novo Holdings announced its financial results for 2025. Despite a challenging global environment, Novo Holdings has made significant progress on its Strategy 2030 during 2025 and delivered on its priorities. The Novo Holdings Investment Portfolio continued to perform well on both an absolute and relative basis, with a return […]
👥London Life Sciences Week 2025 The busiest week in European life sciences is approaching and Optimum and Catalyst Advisors are here to help you maximise your week. Download our events schedule here to plan ahead, connect smart, and make every moment count! If you have any additional events that you would like to be included, […]
AMS announced its Interim results for the six months ended 30 June 2025 This week Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announced its unaudited interim results for the six months ended 30 June 2025. Group revenue increased by 63% to £110.8 million and by 66% at constant currency […]
AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]
Funding enables AMSilk to scale industrial production and meet global customer demand for biotech produced silk-based protein materials The financing round was led by existing investor ATHOS (AT Newtec), with strong participation from fellow existing investors MIG Capital and Novo Holdings The total EUR 52M includes EUR 30M in cash and EUR 22M in convertible […]
